Instil Bio, Inc. (TIL)
| Market Cap | 48.36M -59.2% |
| Revenue (ttm) | n/a |
| Net Income | -30.28M |
| EPS | -4.47 |
| Shares Out | 6.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,186 |
| Open | 7.12 |
| Previous Close | 7.17 |
| Day's Range | 7.03 - 7.16 |
| 52-Week Range | 5.67 - 21.98 |
| Beta | 1.92 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About TIL
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Financial Performance
Financial StatementsNews
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second qua...
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quart...
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current op...
Instil Bio downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Instil Bio (TIL) to Neutral from Buy without a price target saying AXN-2510’s discontinuation eliminates the stock’s core value driver. Investors sho...
Baird downgrades Instil Bio on discontinuation of AXN-2510
Baird analyst Jack Allen downgraded Instil Bio (TIL) to Neutral from Outperform with a price target of $7, down from $180. The stock in midday trading is down 47%, or…
Instil Bio downgraded to Neutral from Outperform at Baird
Baird downgraded Instil Bio (TIL) to Neutral from Outperform with a price target of $7, down from $180, after the company discontinued clinical development of AXN-2510.
Instil Bio’s Axion discontinues clinical development of AXN-2510
Instil Bio (TIL) announced that Axion Bio, a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco Biopharmaceuticals have entere...
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clin...
Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year
As of September 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $83.4 million, which consisted of $5.8 million in cash and cash equival...
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its ...
Instil Bio announces ImmuneOnco presentation of ‘2510 monotherapy data
Instil Bio (TIL) announced that ImmuneOnco Biopharmaceuticals presented preliminary efficacy and safety data of ‘2510 as monotherapy in a Phase 1 study of patients in China with previously treated squ...
Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC...
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
Instil Bio (TIL) noted that ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 in combination with chemothe...
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting...
Instil Bio announces FDA clearance of IND application for AXN-2510
Instil Bio (TIL) announced the clearance of an Investigational New Drug application for AXN-2510 by the U.S. FDA. Instil expects to initiate a phase 1 trial of ‘2510 as monotherapy…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the se...
Instil Bio adds Maraganore to the Board of Directors of Axion Bio
Instil Bio (TIL) announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Instil’s wholly-owned subsidiary dedicated to the development of AXN-2510, a potentially best...
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
DALLAS, June 11, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the...
Instil Bio appoints Jamie Freedman as CMO
Instil Bio (TIL) announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Jamie Freedman is a Hematologist-Oncologist and seasoned biopharmaceutical executive with over 20 y...
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announ...
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ...
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced tha...
Instil Bio price target raised to $125 from $105 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Instil Bio (TIL) to $125 from $105 and keeps a Buy rating on the shares after the company released Phase 1/2 dose…
Instil Bio price target lowered to $105 from $110 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $105 from $110 and keeps a Buy rating on the shares following the Q1 report. The firm says…